National Institutes Of Health
NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants with Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 1, open-label study evaluating the safety and efficacy of adoptive transfer of autologous NY-ESO-1 CD8-TCR engineered T cells and NY-ESO-1 CD4-TCR engineered hematopoietic stem cells after a myeloablative conditioning regimen, with administration of IL-2 in patients with relapsed or treatment-refractory ovarian, fallopian tube or primary peritoneal cancer.
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
HA-1 T TCR T Cell Immunotherapy for the Treating of Patients with Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
The Wistar Institute researcher receives NIH New Innovator Award
Second Sight given $2.4 million NIH grant
AACR Cancer Progress Report: Past federal investments in NIH spurring breakthroughs in care
Lumpers, Splitters, and the Move Toward New Taxonomy for Rheumatology

Historians attribute Philip II of Macedon — father of Alexander the Great — as the source of the motto and political principle known as “divide and conquer.” As a ruling technique, the maxim worked, with Phillip ultimately ruling over most of classical Greece; a success that would be repeated with Julius Caesar and Napoleon Bonaparte in the centuries to follow.
New findings provide additional evidence of AFM, enterovirus link
Testing of 14 patients with acute flaccid myelitis, or AFM, showed they had antibodies against enteroviruses, especially EV-D68, in their cerebrospinal fluid at a significantly higher rate than controls, supporting “the plausibility of a link” between enterovirus infection and AFM, researchers reported in mBio.